Immunohistochemical evaluation of e-cadherin, Ki-67 and PCNA in canine mammary neoplasias: Correlation of prognostic factors and clinical outcome

Pesquisa Veterinaria Brasileira

Volumn 28, Issue 4, 2008, Pages 207-215

  Zuccari, Debora A P C ^a   Pavam, Marcilia V ^a   Terzian, Ana Carolina B ^b   Pereira, Rodrigo S ^c   Ruiz, Camila M ^d   Andrade, Joanna Coelho ^e  

^a FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c Centro Universitario de Rio Preto   (Brazil)

^d VETPAT Laboratório de Patologia e Biologia Molecular Veterinária   (Brazil)

^e VETPAT Laboratório de Patologia e Biologia Molecular Veterinária ^*

Author keywords

Canine; Cell proliferation marker; E cadherin; Immunohistochemistry; Mammary neoplasm

Indexed keywords

CANIS FAMILIARIS;

EID: 45849116447     PISSN: 0100736X     EISSN: 16785150     Source Type: Journal    
DOI: 10.1590/s0100-736x2008000400003     Document Type: Article

References (60)

1. Allred C.D., Harvey J.M., Berardo M. & Clark G.M. 1998. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern Pathol. 11(2):155-168.
2. Asgeirsson K.S., Jonasson J.G., Tryggvadorttir L., Olafsdottir K., Sigurgeirsdottir J.R., Ingvarsson S. & Ogmundsdottir H.M. 2000. Altered expression of E-cadherin in breast cancer: patterns, mechanisms and clinical significance. Eur. J. Cancer 36:1098-1106.
3. Berx G. & Roy F.V. 2001. The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenes and malignant progression. Breast Cancer Res. 3:289-293.
4. Bouzubar N., Walker K.J., Griffiths K., Ellis I.O., Elston C.W., Robertson J.F., Blamey R.W. & Nicholson R.I. 1989. Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Brit. J. Cancer 59(6):943-947.
5. Bravo R., Frank R., Blundell P.A. & MacDonald-Bravo H. 1987. Cyclin/PCNA is the auxiliary proyein of polimerase-d. Nature 326(6112):515-517.
6. Brunetti B., Sarli G., Preziosi R., Monari I. & Benazzi C. 2005. E-cadherin and β-catenin reduction influence invasion but not proliferation and survival in canine malignant mammary tumors. Vet. Pathol. 42:781-787.
7. Bruno S. & Darzynkiewicz Z. 1992. Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cell. Cell Prolif. 25(1):31-40.
8. Charpin C., Garcia S., Bouvier C., Devictor B., Andrac L., Choux R. & Lavaut M. 1997. E-cadherin quantitative immunocytochemical assays in breast carcinomas. J. Pathol. 181:294-300.
9. Delahunt B., Betwaite P.B., Thornton A. & Ribas J.L. 1995. Proliferation of renal cell carcinoma assessed by fixation-resistant polyclonal Ki-67 antibody labeling: correlation with clinical outcome. Cancer 75:2714-2719.
10. Fitzgibbons P.L., Page D.L., Weaver D., Thor A.D., Allred C., Clark G.M., Ruby S.G., O'Malley F., Simpson J.F., Connolly J.L., Hayes D.F., Edge S.B., Lichter A. & Schnitt S.J. 2000. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch. Pathol. Laborat. Med. 124:966-978.
11. Gamallo C., Palacios J., Suarez A., Pizarro A., Navarro P., Quintanilla M. & Cano A. 1993. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am. J. Pathol. 142:987-993.
12. Gasparini G., Boracchi P., Verderio P. & Bevilacqua P. 1994. Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. St Bortolo Medical Centre, Vicenza, Italy.
13. Gerdes J., Lemke H., Baisch H., Wacker H.H., Schwab U. & Stein H. 1984. Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 133:1710-1715.
14. Gerdes J., Becker M.H.G. & Key G. 1992. Immunohistological detection of tumor growth fraction (Ki-67 antigen) in formalin fixed and routinely tissues. J. Pathol. 168(1):85-87.
15. Gillett C.E., Miles D.W., Ryder K., Skilton D., Liebman R.D., Springall R.J., Barnes D.M. & Hanby A.M. 2001. Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J. Pathol. 193:433-441.
16. Glukchova M., Koteliansky V. & Sastre X. 1995. Adhesion systems in normal breast and in invasive breast carcinoma. Am. J. Pathol. 146:706-716.
17. Guriec N., Marcellin L., Gairard B., Caldéroli H., Wilk A., Renaud R., Bergerat J.P. & Oberling F. 1996. E-cadherin mRNA expression in breast carcinomas correlates with overall and disease-free survival. Invasion and Metastasis 16:19-26.
18. Heimann T., Lan F.S., McBride R. & Hellman S. 2000. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin. Cancer Res. 60:298-304.
19. Huang W.Y., Coltrera M., Schubert M., Morton T. & Truelove E. 1994. Histopathologic evaluation of proliferating cell nuclear antigen (PC10) in oral epithelial hyperplasias and premalignat lesions. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 78(6):748-754.
20. Kovacs A., Dhillon J. & Walker R.A. 2003. Expression of P-cadherin, but not E-cadherin or N-cadherin, relates to pathological and functional differentiation of breast carcinomas. Molecular Pathol. 56:318-322.
21. Kowalsky P.J., Rubin M.A. & Kleer C.G. 2003. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res. 5:217-222.
22. Kushlinskii N.E., Orinovskii M.B., Gurevich L.E., Kazantseva I.A., Talaeva ShZh, Ermilova V.D., Dvorova E.K., Ozherel'ev A.S. & Letiagin V.P. 2004. The specificity of expression of molecular biological markers in tumors of the mammary gland. Vestn. Ross Akad. Med. Nauk. 5:32-36.
23. Lipponen P., Saaelainen E., Ji H., Aaltomaa S. & Syrjanen K. 1994. Expression of E-cadherin is related to other prognostic factors and survival in breast cancer. J. Pathol. 174:101-109.
24. MacEwen E.G. 1990. Spontaneous tumors in dogs and cats: Models for the study of cancer biology and treatment. Cancer and Metastases Review 9(1):125-136.
25. Martinez-Lara I., Gonzáles-Moles M.A., Ruiz-Avila I., Bravo M., Ramos M.C. & Fernández-Martinez J.A. 1996. Proliferating cell nuclear antigen (PCNA) as a marker of dysplasia in oral mucosa. Acta Stomatol. Belg. 93(1):29-32.
26. Matos A.J.F., Lopes C., Carvalheira J., Santos M., Rutteman G.R. & Gartner F. 2006. E-cadherin expression in canine malignant mammary tumours: relationship to other clinico-pathological variables. J. Comp. Pathol. 134:182-189.
27. McMormick D. & Hall P.A. 1992. The complexities of proliferating cell nuclear antigen. Histopathology 21(6):591-594.
28. Mighell A. 1995. PCNA and p53. Eur. J. Cancer B, Oral Oncology 31(6):403-404.
29. Misdorp W. 2002. Tumors of the mammary gland, p.575-606. In: Meulten D.J. (ed.), Tumors in Domestic Animals. 4th ed. Iowa State Press, Ames.
30. Nowak M., Madej J.A., Dziegiel P. & Kanzawa H. 2006. Immunohistochemical identification method of tumour cells in the S phase of mitotic cycle and its usefulness in diagnostics of mammary gland adenocarcinomas in bitches. Pol. J. Vet. Sci. 9(1):57-62.
31. Oesterreich S., Deng W., Jiang S., Cui X., Inanova M., Schiff R., Kaiyan K., Kang K., Hadsell D.L., Behrens J. & Lee A.V. 2003. Estrogen-mediated down-regulation of E-cadherin in breast câncer cells. Cancer Res. 63:5203-5208.
32. Oyama T., Mitsudomi T., Mizone T., Ohgami T., Nakanishi R. & Yasumoto K. 1995. Proliferating cell nuclear antigen may be superior to argyrophilic nucleolar organizer regions in predicting shortened survival of patients with non-small cell lung cancer. Surg. Oncol. 4:83-89.
33. Pedersen K.B., Nesland J.M. & Maelandsmo G.M. 2002. Expression of S100A4, E-cadherin, α-and β- catenin in breast cancer biopsies. Brit. J. Cancer 87:1281-1286.
34. Pena L.L., Nieto A.I., Perez-Alenza D., Cuesta P. & Castano M. 1998. Immunohistochemical detection of Ki-67 and PCNA in canine mammary tumors: relationship to clinical and pathologic variables. J. Vet. Diagn. Invest. 10(3):237-246.
35. Perez A.M.D.M., Peña L., Del Castilho N. & Nieto A.L. 2000. Factors influencing the incidence and prognosis of canine mammary tumours. Small Anim. Pract. 41(10):476.
36. Pignatelli M., Liu D. & Nasim M. 1992. Morphoregulatory activities of E-cadherin and beta-1 integrins in colorectal tumourcells. Brit. J. Cancer 66:629-634.
37. Pignatelli M. 1993. E-cadherin: a biological marker of tumor differentiation. J. Pathol. 171:81-82.
38. Queiroz L.M.G. 1997. Expressão do PCNA, Ki-67, cerbB-2 e p53 no carcinoma adenóide cístico e adenocarcinoma polimórfico de baixo grau de malignidade de glândula salivar menor. São Paulo. 78p. Tese de Doutorado em Patologia Bucal, Faculdade de Odontologia, Universidade de São Paulo.
39. Rabenhorst S.H., Burini R.C. & Schmitt F.C.L. 1993. Marcadores de proliferação celular. Revta Bras. Patol. Clín. 29(1):24-29.
40. Rabenhorst S., Burini R. & Schmitt F. 1994. Ciclo celular: mecanismos reguladores e marcadores bioquímicos. Revta Bras. Cancerologia 40:141-147.
41. Reis-Filho J.S., Paredes J., Milanezi F. & Schmitt F.C. 2002. Clinicopathological implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast. Cancer 94:2114-2115.
42. Reis A.L., Carvalheira J., Schmitt F.C. & Gärtner F. 2003. Immunohistochemical study of the expression of E-cadherin in canine mammary tumours. Vet. Rec. 152:621-624.
43. Restucci B., Papparella S., De Vico G. & Maiolino P. 1997. E-cadherin expression in normal and neoplastic canine mammary gland. J. Comp. Pathol. 116:191-202.
44. Rutteman G.R., Withrow S.J. & MacEwen E.G. 2001. Tumors of the mammary gland, p.455-477. In: Withrow S.J. & MacEwen E.G.W.B. (ed.), Small Animal Clinical Oncology. 3rd ed. W.B. Saunders, Philadelphia.
45. Sanchez Y. & Elledge S.J. 1995. Stopped for repairs. Bioessays 17:545-548.
46. Siitonen S.M., Kononen J.T., Helin H.J., Rantala I.S. & Isola J.J. 1996. Reduced E-cadherin expression is associated with invasiveness and unfavourable prognosis in breast cancer. Am. J. Clin. Pathol. 105:394-402.
47. th Acvim Forum, p.387-388.
48. Tahan S.R., Neuberg D.S., Dieffenbach A. & Yacoub L. 1993. Prediction of Early Relapse and Shortened Survival in Patients with Breast Cancer by Proliferating Cell Nuclear Antigen Score. Department of Pathology, New England Deaconess Hospital, Boston, MA 02215.
49. Takeishi M. 1991. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251:1451-1455.
50. Thomas M., Noguchi M., Kitagawa H., Kinoshita K. & Miyazaki I. 1993. Poor Prognostic Value of Proliferating Cell Nuclear Antigen Labelling Index in Breast Carcinoma. Second Department of Surgery, Kanazawa University Hospital, Japan.
51. Thomas E. & Berner G. 2000. Prognostic and predictive implications of HER2 status for breast cancer patients. Eur. J. Oncology Nursing 4:10-17. Disponível em: 〈http//www.idealibrary.com.br〉. Acesso em: 8 jan. 2001
52. Tsuji T., Shrestha P., Yamada K., Shinozaki F., Sasaki K., Maeda K. & Mori M. 1992. Proliferating cell nuclear antigen in malignant and pre-malignant lesions of epithelial origin in the oral cavity and skin: an immunohistochemical study. Virchows Archiv A, Pathol. Anat. 420:377-383.
53. Van T., Veer L.J., Dai H., Van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., Van der Kooy K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R. & Friend S.H. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536.
54. Veronese S.M., Gambacorta M., Gottardi O., Scanzi F., Ferrari M. & Lampertico P. 1993. Proliferation Index as a Prognostic Marker in Breast Cancer. Department of Pathology, Niguarda, Ca, Granda Hospital, Milan, Italy.
55. WHO (World Health Organization). Histological Classification of Tumors of Domestic Animals by the Armed Forces Institute of Pathology AFIP. Disponível em 〈http://www.afip.org/vetpath/who/whomamm.htm〉. Acesso em: 05 jul. 2007.
56. Wintzer H.O., Zipfel I., Schulte-Mönting J., Hellerich U. & Von Kleist S. 1991. Ki-67 immunostaining in Human Breast Tumors and its Relationship to Prognosis. Institute of Immunobiology, University of Freiburg, Federal Republic of Germany.
57. Zacchetti A., Van Garderen E., Teske E., Nederbragt H., Dierendonck J.H. & Rutteman G.R. 2003. Validation of the use of proliferation markers in canine neoplastic and non-neoplastic tissues: comparison of KI-67 and proliferating cell nuclear antigen (PCNA) expression versus in vivo bromodeoxyuridine labelling by immunohistochemistry. APMIS 111(3):430-438.
58. Zschiesche W., Schonborn I., Behrens J., Herrenknecht K., Hartveit F., Lilleng P. & Birchmeier W. 1997. Expression of E-cadherin and catenins in invasive mammary carcinomas. Anticancer Res. 17:561-568.
59. Zuccari D.A.P.C. 2001. Estudo imunocitoquímico de marcadores diagnósticos e prognósticos em neoplasias mamárias caninas. Tese de Doutorado em Clínica Médica Veterinária, Faculdade de Ciências Agrárias e Veterinárias, Unesp-Jaboticabal, SP. 92p.
60. Zuccari D.A.P.C., Santana A.E., Cury P.M., Cordeiro J.A. & Zancheta D. 2004. Immunocytochemical study of Ki-67, as a prognostic marker in canine mammary neoplasias. Vet. Clin. Pathol. 33(1):23-28.